Monograph Details
|
|
Neoplasms
> Miscellaneous oncology agents
|
|
UVADEX |
| Manufacturer |
|
Therakos, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Photoactive agent. |
| Generic Name |
|
Methoxsalen 20mcg/mL; sterile soln. |
| Indications |
|
Extracorporeal administration with the UVAR Photopheresis System in the palliative treatment of skin manifestations of cutaneous T-cell lymphoma that is unresponsive to other forms of treatment. |
| Children |
|
Not recommended. |
| Adults |
|
Consult UVAR Photopheresis System Operator's Manual before administering. Give on two consecutive days every 4 weeks for minimum of 7 treatment cycles (6 months). 200mcg per photopheresis treatment. Accelerated treatment schedule: see literature. |
| Contraindications |
|
Idiosyncratic reactions to psoralen compounds. History of light sensitive disease. Lupus erythematosus. Porphyria cutanea tarda. Erythropoietic protoporphyria. Variegate porphyria. Xeroderma pigmentosum. Albinism. Aphakia. |
| Precautions |
|
Exposure to sun or UV light may cause actinic degeneration, skin burning, cataracts; wear UVA-absorbing, wrap-around sunglasses and cover exposed skin (or use sunblock: SPF ≥15) for 24hrs after treatment. Basal cell carcinomas (monitor and treat if occur). Pregnancy (Cat.D); nursing mothers: not recommended. |
| Interactions |
|
Increased photosensitivity with anthralin, coal tar, griseofulvin, phenothiazines, nalidixic acid, halogenated salicylanilides, sulfonamides, tetracyclines, thiazides, organic staining dyes. |
| Adverse Reactions |
|
Hypotension secondary to changes in extracorporeal volume. |
| How Supplied |
|
Vials (10mL)—12 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
